WHO WE ARE

PolyMedics Innovations (PMI) is an R&D-driven company specializing in innovative biomaterials for the effective treatment of wounds.

We are also

The company that brought about a paradigm shift in treating burn injuries with SUPRATHEL®

We are also

A focused team driven by the ambition to revolutionize wound healing

We are also

A private, self-funded, and self-sustaining company

WHAT DRIVES US:

PATIENTS

PHYSICIANS

AND SOCIETY

For patients suffering from wounds, this means raising their quality of life and accelerating the healing process to get them back to a healthy productive life. To that end, we make products accessible to as many people as possible. PMI’s pioneering synthetic skin products are now available in over 40 markets worldwide and this is the reason we expand our global footprint every single year. As a technology company at heart, we invest FAR above the industry average into research and development at our state-of-the-art headquarters and laboratories in Kirchheim unter Teck, Germany.  Stay tuned for further development and adaptation of our concepts to new products – the best is yet to come. We will continue our joint efforts with medical technology companies that provide our customers with the most comprehensive wound care solutions.

For all health care providers, we provide products that help them do their job as efficiently, successfully, and straightforwardly as possible. Our goal is to provide the clinical community with the most effective, easiest-to-use, and innovative solutions imaginable.

For society, we help reduce the effort and costs required to not only treat acute and chronic wounds, but to heal them. Faster and more effective recovery means a more productive and happier society – and we couldn’t be more proud to be part of the solution.

Improving wound care for patients, physicians, and societies through innovation and collaboration.

Revolutionizing wound healing.

Our four key values that drive our actions: Care, Innovation, Entrepreneurship, Excellence

Where we come from

The story of PMI begins with a long-cherished dream of developing an artificial skin replacement and a person who would not be dissuaded from his goal. Professor Dr. Heinrich Planck would have preferred to study medicine, but chose mechanical engineering for the sake of his father. He devoted himself to the subject close to his heart as early as his diploma thesis, which dealt with a bionically-optimized vascular prosthesis. His 30 years experience in developing synthetic biomaterials were the basis of making the dream of a synthetic skin substitute come true.

SUPRATHEL®, invented by a team of five scientists under the direction of Prof. Planck, revolutionized burn care and brought PMI to life. The result of this effort has become an internationally active company. The concept behind SUPRATHEL® laid the foundation for further product innovations that have the potential to herald a paradigm shift in wound care, starting with SUPRA SDRM®.

1997

BMOZ starts the BMBF project “Development of a wound dressing for burns” with over €500,000 in funding.

1998

The highly porous “V16” membrane, later known as SUPRATHEL®, meets its developers’ requirements.

1999

V16 is first used to treat burns at Marienhospital Stuttgart, yielding results so impressive that doctors deem conventional treatment irresponsible.

2001

Worldwide patent protection and brand name “SUPRATHEL®”.

The five inventors of SUPRATHEL® found PMI, taking over the invention’s rights.

2002

Start of a randomized clinical study at Marienhospital Stuttgart and the BG-Klinik Berlin-Marzahn.

2004

CE Mark for SUPRATHEL® for use in 2° burns (2a and 2b) and for split skin removal.

2005

Extended CE Mark for SUPRATHEL® for mixed-grade 2° and 3° burns. By the end of the year, more than 1,000 patients have been treated with SUPRATHEL®.

2006

First international SUPRATHEL® symposium in October in Berlin.

2007

More than 3,000 patients treated with SUPRATHEL® and the product is in use in around 15 countries. In Germany, Austria, and Switzerland alone, it is used consistently in more than 120 clinics.

2008

SUPRATHEL is launched in France. More than than 4,000 people have now been treated with SUPRATHEL®.

2009

510(k) clearance from the FDA for SUPRATHEL® in the USA.

2010

SUPRATHEL® is produced in the new company facility in Denkendorf. SUPRATHEL® obtains regulatory clearance in South Korea.

2012

SUPRATHEL® obtains market approval in Mexico.

2014

At the ABA in Boston, PMI presents SUPRATHEL® for the first time as a “Synthetic Resorbable Epithelium Skin Substitute” – not as a dressing material or wound dressing. Christian Planck, the second generation of the family, joins the management of the company.

2015

PMI opens US subsidiary in Atlanta.

2017

SUPRA SDRM®, a biodegradable matrix wound dressing related to SUPRATHEL®, also receives 510(k) clearance from the FDA in the USA.

2019

SUPRA SDRM® receives CE Mark in Germany and product approval in the European Union. Partnership with PolyNovo Biomaterials Pty Ltd. for the distribution of NovoSorb® BTM in the DACH (Germany, Austria, Switzerland) region.

2022

Recognition – through reimbursement coding – of SUPRATHEL® and SUPRA SDRM® as synthetic skin substitutes. SUPRATHEL® receives MDR approval in Germany.

2023

PMI moves into the new company headquarters in Kirchheim/Teck. SUPRATHEL® is available in almost 40 countries around the world. PMI became sales agent of NexoBrid® by MediWound and ReCell® by Avita Medical in key European markets.

SUPRA SDRM® receives MDR approval in Germany.

Environmental sustainability

KLIMAfit certification

We aim to make our production carbon neutral by 2030. To get there, we have already implemented several measures. We are proud to have received certification in the KLIMAfit Program.

Efficient facilities

Our new headquarters achieves a 45% energy reduction compared to a standard building, utilizing geothermal energy, heat pumps, and optimized windows and shades for temperature control.

Recycled materials

Our new headquarters uses recycled cement in its construction.

Efficient technology

We use highly energy efficient clean room technology.

Waste recycling

We recycle 98% of our waste materials.

Biodegradability

The polymer metabolizes into CO2 and H2O, leaving no toxic substances behind.

Management board

Professor Dr. Heinrich Planck and his son Christian Planck jointly manage the business of PMI as Managing Partners. Prof. Planck, long-time holder of the Chair of Textile Technology at the University of Stuttgart and member of the Board of Managing Directors for the German Institutes of Textile and Fiber Research Denkendorf (DITF), founded PMI together with five scientists in 2001. Christian has been with the company since 2014 and has driven the global expansion of PMI.